Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420040B2 · kind B2 · utility
42Cited by
14References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2007 |
| Grant date | Sep 2, 2008 |
| Priority date | — |
| Expiry date | Feb 22, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.